
Scale Up
Latest News
Latest Videos

More News

Charles River Laboratories’ Dr. Alan K. Smith explains how early commercial planning, modular manufacturing, and AI-driven automation may accelerate scalable manufacturing for cell and gene therapies.

Such targeted private investments underscore the growing importance of early manufacturing scale-up in de-risking immunomodulatory biologics for neurodegenerative diseases.

Charles River has launched a second cohort to speed CGT innovation with technical guidance and scalable manufacturing support.

Codexis and Nitto Denko Avecia aim to advance next-gen siRNA production methods for improving scalability of RNA therapeutics.

The addition of the two larger-volume bioreactor sizes to Cytiva’s Xcellerex X-platform portfolio will allow scientists and researchers to scale up from 50 L to 2000 L to meet growing demand for clinical trials and regulatory approved products.

Edwin Stone, PhD, CEO of Cellular Origins, offers his unique perspective to the challenges facing CGT manufacturers, drawing on his background in robotics and life science automation.

Jason C. Foster, CEO and executive director of Ori Biotech, spoke on addressing bottlenecks in CGT manufacturing and what to expect in the CGT manufacturing space moving forward.

This is the latest facility launch for BioDuro, following a kilogram laboratory and compound management center, both on the same site, in October 2024.

Platform processes and effective risk assessments help overcome time and cost challenges.

The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.

Taking a brief status check on the biologics supply chain and any impact on scale up operations.

Sterling is known as a global contract development and manufacturing organization, and their network spreads to a manufacturing site in Cramlington, United Kingdom, a recently GMP-licensed dedicated bioconjugation facility in Deeside, and a 111-acre site in Ringaskiddy, Ireland.

Innovations in downstream processing accelerate development, enhance efficiency, and promote sustainability.

Scale-up strategies for cell culture will require a deep understanding of overall bioprocess workflows.

Scaling cell therapy production workflows requires the establishment of closed, automated steps.












